Achmea Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Achmea Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-221	Closed	-$20K	–	509
2023 Q2	$20K	Hold	221	–	–	﹤0.01%	628
2023 Q1	$22K	Hold	221	–	–	﹤0.01%	593
2022 Q4	$21K	Hold	221	–	–	﹤0.01%	610
2022 Q3	$19K	Hold	221	–	–	﹤0.01%	610
2022 Q2	$19K	Hold	221	–	–	﹤0.01%	599
2022 Q1	$17K	Hold	221	–	–	﹤0.01%	626
2021 Q4	$19K	Hold	221	–	–	﹤0.01%	342
2021 Q3	$17K	Buy	+221	New	+$17.4K	﹤0.01%	608
2020 Q3	–	Sell	-1,014	Closed	-$125K	–	490
2020 Q2	$125K	Hold	1,014	–	–	﹤0.01%	269
2020 Q1	$86K	Buy	+1,014	New	+$87.4K	﹤0.01%	232
2017 Q2	–	Sell	-2,554	Closed	-$224K	–	514
2017 Q1	$224K	Buy	+2,554	New	+$227K	0.01%	513

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Achmea Investment Management's BMRN Position: Q3 2023 in Review

Achmea Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 221 shares — an estimated $20K sold.

Achmea Investment Management first reported a position in BMRN in Q1 2017 and held it in 11 quarters. The position peaked at $224K in Q1 2017. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Achmea Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Achmea Investment Management sold 221 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $20K.
Achmea Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Achmea Investment Management's BioMarin Pharmaceuticals position peaked at $224K in Q1 2017.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Achmea Investment Management's 13F filing for Q3 2023, filed 6 Nov 2023.